A novel drug is showing promise for helping improve cognition in patients with mild to moderate Alzheimer’s disease (AD), according to new topline results. A phase 3 trial of more than 800 patients showed that those who were randomly assigned to receive oral GV-971 (Green Valley Pharmaceutical Co, China) met the primary endpoint of significant change from baseline to week 36 on the 12-item cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-Cog 12) compared with those who received placebo. “GV-971 is a novel, marine-derived oligosaccharide, which has multi-targeting mechanisms, including inhibition of amyloid-β fibril formation, neuroinflammation, and recondition of dysbiosis of gut microbiota.

Read More